Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 63 | 2024 | 3610 | 9.900 |
Why?
|
Myelodysplastic Syndromes | 41 | 2024 | 1393 | 6.890 |
Why?
|
Sulfonamides | 13 | 2024 | 1973 | 2.330 |
Why?
|
Primary Myelofibrosis | 4 | 2021 | 208 | 2.270 |
Why?
|
Azacitidine | 11 | 2024 | 336 | 2.060 |
Why?
|
Leukocytosis | 5 | 2020 | 251 | 2.030 |
Why?
|
Hematopoietic Stem Cell Transplantation | 16 | 2024 | 5663 | 1.960 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2024 | 11729 | 1.550 |
Why?
|
Antimetabolites, Antineoplastic | 7 | 2019 | 643 | 1.540 |
Why?
|
Salvage Therapy | 5 | 2023 | 1264 | 1.390 |
Why?
|
Leukemia, Promyelocytic, Acute | 2 | 2019 | 251 | 1.180 |
Why?
|
Leukapheresis | 4 | 2020 | 134 | 1.100 |
Why?
|
Cytarabine | 5 | 2024 | 697 | 1.070 |
Why?
|
Isocitrate Dehydrogenase | 5 | 2024 | 929 | 1.050 |
Why?
|
Interferon-alpha | 2 | 2020 | 920 | 1.040 |
Why?
|
Remission Induction | 7 | 2024 | 2394 | 0.980 |
Why?
|
Immunologic Factors | 3 | 2019 | 1588 | 0.930 |
Why?
|
Chromosome Inversion | 1 | 2024 | 120 | 0.900 |
Why?
|
Thrombocythemia, Essential | 2 | 2024 | 112 | 0.880 |
Why?
|
DNA Methylation | 7 | 2024 | 4383 | 0.870 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2024 | 321 | 0.860 |
Why?
|
Mutation | 20 | 2024 | 30025 | 0.840 |
Why?
|
Graft vs Host Disease | 5 | 2023 | 3028 | 0.840 |
Why?
|
Histone Deacetylase Inhibitors | 2 | 2017 | 774 | 0.750 |
Why?
|
Neoplasms, Second Primary | 3 | 2024 | 1051 | 0.720 |
Why?
|
fms-Like Tyrosine Kinase 3 | 5 | 2024 | 495 | 0.690 |
Why?
|
Tretinoin | 2 | 2019 | 519 | 0.680 |
Why?
|
Disease Management | 7 | 2024 | 2501 | 0.660 |
Why?
|
Hydroxyurea | 1 | 2020 | 282 | 0.650 |
Why?
|
Immunotherapy | 8 | 2023 | 4649 | 0.650 |
Why?
|
Carcinogens | 1 | 2021 | 451 | 0.640 |
Why?
|
Polycythemia Vera | 1 | 2020 | 160 | 0.640 |
Why?
|
Leukemia | 3 | 2022 | 1522 | 0.630 |
Why?
|
Pyrazoles | 3 | 2018 | 2007 | 0.600 |
Why?
|
Humans | 110 | 2024 | 760437 | 0.550 |
Why?
|
Myeloproliferative Disorders | 5 | 2024 | 611 | 0.540 |
Why?
|
Leukemia, Neutrophilic, Chronic | 1 | 2016 | 13 | 0.540 |
Why?
|
Receptors, Colony-Stimulating Factor | 1 | 2016 | 50 | 0.540 |
Why?
|
Neutropenia | 1 | 2021 | 884 | 0.520 |
Why?
|
Transplantation Conditioning | 3 | 2023 | 1588 | 0.520 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2016 | 97 | 0.500 |
Why?
|
Nuclear Proteins | 4 | 2024 | 5794 | 0.500 |
Why?
|
Janus Kinase 2 | 2 | 2024 | 544 | 0.490 |
Why?
|
Prognosis | 21 | 2024 | 29551 | 0.480 |
Why?
|
Steroids | 1 | 2019 | 928 | 0.460 |
Why?
|
Hematinics | 1 | 2017 | 282 | 0.460 |
Why?
|
Culture | 1 | 2018 | 623 | 0.460 |
Why?
|
Molecular Targeted Therapy | 8 | 2024 | 2805 | 0.460 |
Why?
|
Epigenesis, Genetic | 5 | 2024 | 3782 | 0.450 |
Why?
|
DNA, Neoplasm | 1 | 2019 | 1745 | 0.440 |
Why?
|
Interferons | 1 | 2017 | 704 | 0.440 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2015 | 449 | 0.410 |
Why?
|
Thalidomide | 2 | 2017 | 885 | 0.410 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2117 | 0.400 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2016 | 727 | 0.400 |
Why?
|
Antineoplastic Agents | 8 | 2024 | 13616 | 0.400 |
Why?
|
Hemorrhage | 2 | 2024 | 3414 | 0.400 |
Why?
|
Lymphoma | 1 | 2021 | 1901 | 0.400 |
Why?
|
Thiazolidines | 1 | 2011 | 69 | 0.390 |
Why?
|
Hematologic Neoplasms | 3 | 2018 | 1890 | 0.370 |
Why?
|
Glyburide | 1 | 2011 | 116 | 0.370 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2019 | 9267 | 0.360 |
Why?
|
Transplantation, Homologous | 6 | 2023 | 4808 | 0.350 |
Why?
|
Glycine | 2 | 2024 | 665 | 0.350 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1549 | 0.350 |
Why?
|
Benzoates | 1 | 2011 | 211 | 0.340 |
Why?
|
Hydrazines | 1 | 2011 | 224 | 0.340 |
Why?
|
Drug Delivery Systems | 1 | 2021 | 2224 | 0.340 |
Why?
|
Androgens | 1 | 2017 | 1282 | 0.330 |
Why?
|
Neoplasms | 7 | 2023 | 22083 | 0.330 |
Why?
|
Tumor Suppressor Protein p53 | 6 | 2024 | 2911 | 0.330 |
Why?
|
Antiviral Agents | 2 | 2022 | 3066 | 0.320 |
Why?
|
Retrospective Studies | 17 | 2024 | 80430 | 0.320 |
Why?
|
Neoplasm, Residual | 3 | 2022 | 1008 | 0.310 |
Why?
|
Treatment Outcome | 18 | 2024 | 64591 | 0.310 |
Why?
|
Nitriles | 3 | 2018 | 969 | 0.290 |
Why?
|
Cell Cycle Proteins | 3 | 2024 | 3446 | 0.290 |
Why?
|
Antilymphocyte Serum | 2 | 2019 | 483 | 0.280 |
Why?
|
Chromosomal Proteins, Non-Histone | 2 | 2024 | 726 | 0.280 |
Why?
|
Daunorubicin | 2 | 2024 | 156 | 0.280 |
Why?
|
Combined Modality Therapy | 4 | 2024 | 8522 | 0.270 |
Why?
|
Disease-Free Survival | 4 | 2020 | 6813 | 0.260 |
Why?
|
Chromosomes, Human, Pair 5 | 2 | 2017 | 385 | 0.250 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 1741 | 0.250 |
Why?
|
Aged | 26 | 2024 | 168840 | 0.240 |
Why?
|
Standard of Care | 2 | 2019 | 550 | 0.240 |
Why?
|
Thrombocytosis | 1 | 2024 | 87 | 0.240 |
Why?
|
Drug Therapy, Combination | 4 | 2019 | 6297 | 0.240 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 3880 | 0.230 |
Why?
|
Clinical Trials as Topic | 8 | 2023 | 7996 | 0.230 |
Why?
|
Benzothiazoles | 1 | 2024 | 247 | 0.210 |
Why?
|
Cell Differentiation | 2 | 2024 | 11526 | 0.210 |
Why?
|
Myelodysplastic-Myeloproliferative Diseases | 1 | 2022 | 15 | 0.210 |
Why?
|
Adult | 22 | 2024 | 220781 | 0.210 |
Why?
|
Survival Analysis | 4 | 2018 | 10075 | 0.200 |
Why?
|
Aged, 80 and over | 13 | 2024 | 58859 | 0.190 |
Why?
|
Anthracyclines | 1 | 2023 | 284 | 0.190 |
Why?
|
Middle Aged | 21 | 2024 | 220382 | 0.190 |
Why?
|
Drug Design | 2 | 2016 | 1050 | 0.180 |
Why?
|
Cytogenetic Analysis | 1 | 2021 | 270 | 0.180 |
Why?
|
Phenylurea Compounds | 1 | 2024 | 528 | 0.180 |
Why?
|
Pyrimidines | 3 | 2018 | 3024 | 0.180 |
Why?
|
Pteridines | 1 | 2020 | 47 | 0.180 |
Why?
|
Leukostasis | 1 | 2020 | 23 | 0.180 |
Why?
|
Survival Rate | 5 | 2024 | 12698 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2024 | 1404 | 0.170 |
Why?
|
Hematology | 1 | 2023 | 244 | 0.170 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 10180 | 0.170 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 677 | 0.170 |
Why?
|
Telomerase | 1 | 2024 | 745 | 0.160 |
Why?
|
Nuclear Pore Complex Proteins | 1 | 2020 | 163 | 0.160 |
Why?
|
Stem Cell Transplantation | 3 | 2022 | 1598 | 0.160 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 359 | 0.160 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2024 | 500 | 0.160 |
Why?
|
Male | 23 | 2024 | 360035 | 0.150 |
Why?
|
Prednisolone | 1 | 2018 | 326 | 0.140 |
Why?
|
Tumor Escape | 2 | 2020 | 370 | 0.140 |
Why?
|
Hematopoiesis | 2 | 2024 | 2049 | 0.140 |
Why?
|
Patients | 1 | 2023 | 905 | 0.140 |
Why?
|
Anemia, Macrocytic | 1 | 2017 | 53 | 0.140 |
Why?
|
Chromosome Aberrations | 1 | 2023 | 1771 | 0.140 |
Why?
|
Pulmonary Edema | 1 | 2019 | 408 | 0.140 |
Why?
|
Incidence | 4 | 2024 | 21322 | 0.130 |
Why?
|
Female | 24 | 2024 | 391875 | 0.130 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2024 | 1605 | 0.130 |
Why?
|
Leukocyte Count | 1 | 2020 | 1596 | 0.130 |
Why?
|
Immunosuppressive Agents | 2 | 2019 | 4168 | 0.130 |
Why?
|
Oncogene Proteins | 1 | 2020 | 718 | 0.130 |
Why?
|
Natriuretic Peptide, C-Type | 1 | 2015 | 18 | 0.130 |
Why?
|
Tumor Microenvironment | 3 | 2019 | 3874 | 0.130 |
Why?
|
Enzyme Inhibitors | 2 | 2024 | 3710 | 0.130 |
Why?
|
Paraneoplastic Syndromes | 1 | 2017 | 155 | 0.130 |
Why?
|
Recombinant Fusion Proteins | 1 | 2024 | 3734 | 0.120 |
Why?
|
Cancer Vaccines | 2 | 2020 | 1050 | 0.120 |
Why?
|
Granuloma | 1 | 2017 | 327 | 0.120 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 223 | 0.120 |
Why?
|
Immunomodulation | 1 | 2018 | 547 | 0.120 |
Why?
|
Patient Selection | 2 | 2017 | 4240 | 0.120 |
Why?
|
Erythrocyte Transfusion | 1 | 2019 | 565 | 0.120 |
Why?
|
Atrial Natriuretic Factor | 1 | 2015 | 350 | 0.110 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 5491 | 0.110 |
Why?
|
Antibodies, Bispecific | 1 | 2016 | 196 | 0.110 |
Why?
|
Hypotension | 1 | 2019 | 879 | 0.110 |
Why?
|
Risk Assessment | 4 | 2023 | 23953 | 0.110 |
Why?
|
Skin | 2 | 2017 | 4474 | 0.110 |
Why?
|
Syndrome | 1 | 2019 | 3267 | 0.110 |
Why?
|
Immunotherapy, Adoptive | 2 | 2020 | 1463 | 0.110 |
Why?
|
Infection Control | 1 | 2020 | 985 | 0.110 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2413 | 0.110 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2015 | 483 | 0.100 |
Why?
|
Drug Discovery | 2 | 2019 | 1054 | 0.100 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7380 | 0.100 |
Why?
|
Amino Acid Substitution | 1 | 2017 | 1737 | 0.100 |
Why?
|
Chromatin | 1 | 2024 | 2951 | 0.100 |
Why?
|
RNA Splicing | 3 | 2023 | 915 | 0.100 |
Why?
|
Chromosome Deletion | 1 | 2017 | 1387 | 0.100 |
Why?
|
Squalus acanthias | 1 | 2011 | 5 | 0.100 |
Why?
|
Fundulidae | 1 | 2011 | 12 | 0.100 |
Why?
|
Xenopus laevis | 2 | 2015 | 963 | 0.100 |
Why?
|
Animals | 15 | 2024 | 168253 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2020 | 3631 | 0.090 |
Why?
|
Recurrence | 2 | 2020 | 8466 | 0.090 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3876 | 0.090 |
Why?
|
Adolescent | 6 | 2024 | 88196 | 0.090 |
Why?
|
Counseling | 1 | 2018 | 1545 | 0.090 |
Why?
|
Oocytes | 1 | 2015 | 1168 | 0.090 |
Why?
|
Dendritic Cells | 1 | 2021 | 2725 | 0.080 |
Why?
|
Genotype | 1 | 2024 | 12976 | 0.080 |
Why?
|
Stroke Volume | 1 | 2023 | 5487 | 0.080 |
Why?
|
Internet | 2 | 2020 | 3092 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 2 | 2024 | 5662 | 0.080 |
Why?
|
Skin Diseases | 1 | 2017 | 1090 | 0.080 |
Why?
|
Cohort Studies | 2 | 2024 | 41366 | 0.080 |
Why?
|
Mortality | 1 | 2019 | 2897 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 1 | 2020 | 4509 | 0.080 |
Why?
|
Young Adult | 5 | 2024 | 59068 | 0.070 |
Why?
|
Mutation, Missense | 1 | 2017 | 2571 | 0.070 |
Why?
|
Gene Expression | 1 | 2020 | 7582 | 0.070 |
Why?
|
Odds Ratio | 1 | 2020 | 9639 | 0.070 |
Why?
|
Immunity, Innate | 2 | 2018 | 3059 | 0.070 |
Why?
|
Anemia | 1 | 2017 | 1508 | 0.070 |
Why?
|
Survivors | 1 | 2017 | 2369 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2022 | 3344 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2019 | 1925 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2016 | 2821 | 0.070 |
Why?
|
Quality-Adjusted Life Years | 2 | 2024 | 1722 | 0.070 |
Why?
|
Multivariate Analysis | 1 | 2020 | 12054 | 0.070 |
Why?
|
Histones | 1 | 2016 | 2577 | 0.070 |
Why?
|
Logistic Models | 1 | 2020 | 13240 | 0.060 |
Why?
|
Chronic Disease | 1 | 2020 | 9309 | 0.060 |
Why?
|
Risk Factors | 3 | 2024 | 74055 | 0.060 |
Why?
|
Risk | 1 | 2017 | 9605 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2016 | 3469 | 0.060 |
Why?
|
Biopsy | 1 | 2016 | 6765 | 0.060 |
Why?
|
Interleukin-3 Receptor alpha Subunit | 1 | 2024 | 36 | 0.060 |
Why?
|
Chondroitin Sulfate Proteoglycans | 1 | 2024 | 141 | 0.060 |
Why?
|
Consensus | 2 | 2024 | 3115 | 0.060 |
Why?
|
Genome, Mitochondrial | 1 | 2024 | 67 | 0.060 |
Why?
|
Melanoma | 1 | 2022 | 5704 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5292 | 0.050 |
Why?
|
Electrocardiography | 1 | 2016 | 6380 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9176 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2019 | 15820 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39078 | 0.050 |
Why?
|
Databases, Factual | 1 | 2018 | 7948 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3080 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3200 | 0.050 |
Why?
|
Platelet Count | 1 | 2024 | 780 | 0.050 |
Why?
|
Prednisone | 2 | 2017 | 1564 | 0.050 |
Why?
|
Antigens, CD34 | 1 | 2024 | 658 | 0.050 |
Why?
|
Pyridines | 2 | 2024 | 2868 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 13338 | 0.050 |
Why?
|
Thymidine Kinase | 1 | 2022 | 286 | 0.050 |
Why?
|
Ganciclovir | 1 | 2022 | 252 | 0.050 |
Why?
|
Swine | 1 | 2011 | 5915 | 0.050 |
Why?
|
United States | 5 | 2022 | 72202 | 0.050 |
Why?
|
Blast Crisis | 1 | 2021 | 101 | 0.050 |
Why?
|
Methotrexate | 2 | 2018 | 1720 | 0.040 |
Why?
|
Clone Cells | 1 | 2024 | 1660 | 0.040 |
Why?
|
Tumor Lysis Syndrome | 1 | 2020 | 38 | 0.040 |
Why?
|
Disease Progression | 1 | 2017 | 13484 | 0.040 |
Why?
|
Megakaryocytes | 1 | 2024 | 566 | 0.040 |
Why?
|
Amino Acid Sequence | 1 | 2011 | 13445 | 0.040 |
Why?
|
Bone Marrow | 2 | 2023 | 2907 | 0.040 |
Why?
|
Introns | 1 | 2022 | 981 | 0.040 |
Why?
|
Uveal Neoplasms | 1 | 2022 | 341 | 0.040 |
Why?
|
Molecular Sequence Data | 1 | 2011 | 17639 | 0.040 |
Why?
|
Telomere | 1 | 2024 | 931 | 0.040 |
Why?
|
Time Factors | 1 | 2019 | 39947 | 0.040 |
Why?
|
Resource Allocation | 1 | 2020 | 350 | 0.040 |
Why?
|
Expert Testimony | 1 | 2020 | 361 | 0.040 |
Why?
|
Skin Diseases, Viral | 1 | 2017 | 26 | 0.040 |
Why?
|
Dermatomycoses | 1 | 2017 | 48 | 0.040 |
Why?
|
Epigenomics | 1 | 2023 | 940 | 0.040 |
Why?
|
Breast Neoplasms | 2 | 2022 | 20985 | 0.030 |
Why?
|
Skin Diseases, Bacterial | 1 | 2017 | 68 | 0.030 |
Why?
|
Histiocytes | 1 | 2017 | 98 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2024 | 2444 | 0.030 |
Why?
|
Indoles | 1 | 2023 | 1833 | 0.030 |
Why?
|
Biological Therapy | 1 | 2016 | 141 | 0.030 |
Why?
|
Protein Processing, Post-Translational | 1 | 2023 | 1974 | 0.030 |
Why?
|
Tacrolimus | 1 | 2018 | 733 | 0.030 |
Why?
|
Prospective Studies | 1 | 2019 | 54339 | 0.030 |
Why?
|
Multiple Organ Failure | 1 | 2017 | 386 | 0.030 |
Why?
|
RNA | 1 | 2024 | 2721 | 0.030 |
Why?
|
SEER Program | 1 | 2019 | 1449 | 0.030 |
Why?
|
Fibroblasts | 1 | 2024 | 4106 | 0.030 |
Why?
|
Vincristine | 1 | 2016 | 1036 | 0.030 |
Why?
|
RNA-Binding Proteins | 1 | 2022 | 1897 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2022 | 2423 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2018 | 725 | 0.030 |
Why?
|
Signal Transduction | 1 | 2016 | 23397 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20551 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2020 | 1766 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2017 | 1832 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 1994 | 0.020 |
Why?
|
Inflammation | 2 | 2024 | 10746 | 0.020 |
Why?
|
Drug Approval | 1 | 2019 | 811 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2024 | 3396 | 0.020 |
Why?
|
Medicare | 2 | 2019 | 6732 | 0.020 |
Why?
|
Sirolimus | 1 | 2018 | 1533 | 0.020 |
Why?
|
Treatment Failure | 1 | 2017 | 2642 | 0.020 |
Why?
|
Thrombosis | 1 | 2024 | 2940 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2202 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 1663 | 0.020 |
Why?
|
Blood Transfusion | 1 | 2017 | 1299 | 0.020 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2016 | 779 | 0.020 |
Why?
|
Lymphoma, B-Cell | 1 | 2016 | 940 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2018 | 1886 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2015 | 3592 | 0.020 |
Why?
|
Antigens, CD | 1 | 2019 | 4000 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6471 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10759 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2024 | 7849 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2024 | 9598 | 0.020 |
Why?
|
Apoptosis | 1 | 2022 | 9468 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2024 | 11900 | 0.020 |
Why?
|
Health Personnel | 1 | 2020 | 3331 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2022 | 16945 | 0.020 |
Why?
|
Mice | 2 | 2024 | 81402 | 0.020 |
Why?
|
Lung | 1 | 2024 | 9973 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2019 | 4575 | 0.020 |
Why?
|
Pilot Projects | 1 | 2018 | 8611 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 12429 | 0.020 |
Why?
|
Neutrophils | 1 | 2017 | 3764 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2016 | 2204 | 0.010 |
Why?
|
Cytokines | 1 | 2018 | 7377 | 0.010 |
Why?
|
Comorbidity | 1 | 2017 | 10494 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8623 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18379 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2015 | 18955 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20078 | 0.010 |
Why?
|